Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity

[1]  Hong Chang,et al.  Role of CD47 in Hematological Malignancies , 2020, Journal of Hematology & Oncology.

[2]  I. Weissman,et al.  Targeting macrophage checkpoint inhibitor SIRPa for anticancer therapy. , 2020, JCI insight.

[3]  S. Spijkers,et al.  Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα–CD47 innate immune checkpoint , 2019, Journal of Immunotherapy for Cancer.

[4]  J. Pons,et al.  A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma , 2019, Blood.

[5]  C. Drake,et al.  34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1 , 2019, Journal of Immunotherapy for Cancer.

[6]  C. Daige,et al.  34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 2 , 2019, Journal of Immunotherapy for Cancer.

[7]  N. Jahchan,et al.  Tuning the Tumor Myeloid Microenvironment to Fight Cancer , 2019, Front. Immunol..

[8]  C. Usal,et al.  SIRPα/CD47 axis controls the maintenance of transplant tolerance sustained by myeloid‐derived suppressor cells , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[9]  Amy Y. Chen,et al.  Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα , 2019, mAbs.

[10]  F. Hodi,et al.  A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy. , 2019, Journal of Clinical Oncology.

[11]  I. Weissman,et al.  First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Ralph Weissleder,et al.  Successful Anti‐PD‐1 Cancer Immunotherapy Requires T Cell‐Dendritic Cell Crosstalk Involving the Cytokines IFN‐&ggr; and IL‐12 , 2018, Immunity.

[13]  I. Weissman,et al.  CD47 Blockade by Hu5F9‐G4 and Rituximab in Non‐Hodgkin's Lymphoma , 2018, The New England journal of medicine.

[14]  Amy Y. Chen,et al.  ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile , 2018, PloS one.

[15]  yang-xin fu,et al.  Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion. , 2018, Cell reports.

[16]  T. Matozaki,et al.  CD47‐signal regulatory protein α signaling system and its application to cancer immunotherapy , 2018, Cancer science.

[17]  Angela E. Leek,et al.  Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies , 2018, Cancer cell.

[18]  Simon C Watkins,et al.  4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses , 2018, The Journal of experimental medicine.

[19]  Steven J. M. Jones,et al.  The Immune Landscape of Cancer , 2018, Immunity.

[20]  Jedd D. Wolchok,et al.  Cancer immunotherapy using checkpoint blockade , 2018, Science.

[21]  A. Veillette,et al.  SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy. , 2018, Trends in immunology.

[22]  I. Weissman,et al.  Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity , 2017, Proceedings of the National Academy of Sciences.

[23]  R. Weichselbaum,et al.  Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross‐priming through Signal Regulatory Protein &agr; Signaling , 2017, Immunity.

[24]  K. Weiskopf.  Cancer immunotherapy targeting the CD47/SIRPα axis. , 2017, European journal of cancer.

[25]  D. Gabrilovich,et al.  Dendritic cells in cancer: the role revisited. , 2017, Current opinion in immunology.

[26]  H. Matlung,et al.  The CD47‐SIRPα signaling axis as an innate immune checkpoint in cancer , 2017, Immunological reviews.

[27]  T. Komori,et al.  Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy. , 2017, JCI insight.

[28]  Simon J. Dovedi,et al.  Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery , 2016, Cancer Immunology Research.

[29]  S. Trudel,et al.  TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding , 2016, Clinical Cancer Research.

[30]  R. Coffman,et al.  Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells , 2016, Proceedings of the National Academy of Sciences.

[31]  Ryan L. Kelly,et al.  Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses , 2016, Nature Medicine.

[32]  R. Etches,et al.  Expression of heavy chain‐only antibodies can support B‐cell development in light chain knockout chickens , 2016, European journal of immunology.

[33]  K. Garcia,et al.  Durable antitumor responses to CD47 blockade require adaptive immune stimulation , 2016, Proceedings of the National Academy of Sciences.

[34]  R. Mallampalli,et al.  Cleavage of Signal Regulatory Protein α (SIRPα) Enhances Inflammatory Signaling* , 2015, The Journal of Biological Chemistry.

[35]  I. Weissman,et al.  Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential , 2015, PloS one.

[36]  A. Korman,et al.  FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis. , 2015, Cancer cell.

[37]  yang-xin fu,et al.  CD47 Blockade Triggers T cell-mediated Destruction of Immunogenic Tumors , 2015, Nature Medicine.

[38]  J. Ravetch,et al.  Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect , 2015, Cell.

[39]  P. Sharma,et al.  Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential , 2015, Cell.

[40]  Jens-Peter Volkmer,et al.  Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies , 2013, Science.

[41]  F. Bertucci,et al.  CD47–signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction , 2011, Proceedings of the National Academy of Sciences.

[42]  Ash A. Alizadeh,et al.  Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma , 2010, Cell.

[43]  E. Unanue,et al.  Batf3 Deficiency Reveals a Critical Role for CD8α+ Dendritic Cells in Cytotoxic T Cell Immunity , 2008, Science.

[44]  Michael D. Connolly,et al.  Use of Ly6G‐specific monoclonal antibody to deplete neutrophils in mice , 2008, Journal of leukocyte biology.

[45]  J. Dick,et al.  Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells , 2007, Nature Immunology.

[46]  J. Matsuzaki,et al.  Successful elimination of memory-type CD8+ T cell subsets by the administration of anti-Gr-1 monoclonal antibody in vivo. , 2003, Cellular immunology.

[47]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[48]  L. Williamson,et al.  The contrasting IgG-binding interactions of human and herpes simplex virus Fc receptors. , 2002, Biochemical Society transactions.

[49]  K. Zen,et al.  Signal Regulatory Protein (SIRPα), a Cellular Ligand for CD47, Regulates Neutrophil Transmigration* , 2002, The Journal of Biological Chemistry.

[50]  Eric J. Brown,et al.  Bidirectional Negative Regulation of Human T and Dendritic Cells by CD47 and Its Cognate Receptor Signal-Regulator Protein-α: Down-Regulation of IL-12 Responsiveness and Inhibition of Dendritic Cell Activation1 , 2001, The Journal of Immunology.

[51]  Leonard G. Presta,et al.  High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR* , 2001, The Journal of Biological Chemistry.

[52]  P. Parren,et al.  In vitro characterization of five humanized OKT3 effector function variant antibodies. , 2000, Cellular immunology.

[53]  J. Emtage,et al.  The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding. , 1995, Immunology.

[54]  R. Kurlander.  Blockade of Fc receptor-mediated binding to U-937 cells by murine monoclonal antibodies directed against a variety of surface antigens. , 1983, Journal of immunology.